"1 in 10 and Still Counting" Resources

[i] Klaus M. Leisinger, “The Corporate Responsibility of the Pharmaceutical Industry: Idealism Without Illusion and Realism Without Resignation”, 577-594.

[ii] Ibid., 578.

[iii] Ibid., 583.

[iv] Ibid., 583.

[v] Ibid., 583.

[vi] “The Ten Principles of the UN Global Compact”, accessed on April 24, from https:// www.unglobalcompact.org/what-is-gc/mission/principles

[vii] “Corporate Citizenship”, accessed on April 24, 2017, from http://www.investopedia.com/terms/ c/corporatecitizenship.asp

[viii] Leisinger, “CSR and the Pharmaceutical Industry”, 583.

[ix] Peter Moszynski, “High cost of essential drugs forces millions into poverty every year” in Journal of BMJ: British Medical Journal (Online): pp. 343

[x] “Almost 1 in 10 Americans Can’t Afford Medications says CDC” accessed on April 20, 2017, from renalandurologynews.com

[xi] “Investigational New Drug (IND) Application” accessed on April 20, 2017, from https:// www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/InvestigationalNewDrugINDApplication/

[xii] Ibid.

[xiii] Ibid.

[xiv] Ibid.

[xv] “Control”, accessed on April 20, 217 from, google

[xvi] Tim Parker, “8 Stages Of New Drug Development” accessed on April 20, 2017, from http:// www.investopedia.com/articles/investing/072913/8-stages-new-drug-development.asp

[xvii] Tim Parker, “8 Stages Of New Drug Development”

[xviii] “New Drug Application (NDA)”, accessed on April 20, 2017 from, fda.gov

[xix] Tim Parker, “8 Stages Of New Drug Development”

[xx] Rick Mullin, “Cost to Develop New Pharmaceutical Drug Now Exceeds $2.5B” accessed on April 20, 2017 from, scientificamerican.com

[xxi] Developing New Treatments and Cures is a Complex and Risky Undertaking” accessed on April, 21, 2017 from, phrma.org

[xxii] Ibid.

[xxiii] Pedro Cuatrecasas, “Drug discovery in jeopardy” in Journal of The Journal of Clinical Investigation: pp. 2837- 2842

[xxiv] Ibid., 2837.

[xxv] Ibid., 2837.

[xxvi] Leisinger, 585.

[xxvii] Mooney, “The solutions in theory: communitarian claims”, pp: 123-131

[xxviii] Ibid., 124.

[xxix] Ibid., 124.

[xxx] Ibid., 126.

[xxxi] Tom L. Beauchamp, Philosophical Ethics: An introduction to Moral Philosophy, 3rd edition (Boston: McGraw, 2001) pp: 231.

[xxxii] Leisinger, 585.

[xxxiii] Michael Kremer, “Pharmaceuticals and the developing world” in Journal of The Journal of economic perspectives: pp: 68-90

[xxxiv] Mooney, 133.

[xxxv] Michael Walzer, Spheres of Justice, pp: 3-30

[xxxvi] Leisinger, 589.


To learn more about the LMU Bioethics Institute click below.  

LMU Bioethics Institute

Loyola Marymount University Suite 4500

1 LMU Drive

Los Angeles, CA 90045


Tel: 310-258-5417

If you have a bioethics-related event or opportunity you would like featured in our calendar, contact the Bioethics Institute Graduate Assistant, at BioethicsGA@lmu.edu, with relevant information.

© Graduate Students of the LMU Bioethics Institute

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey YouTube Icon